The Early Successful Treatment of Glioblastoma Patients with Modified boron Neutron Capture Therapy
We very effectively treated two patients with recurrent glioblastoma with modified boron neutron capture therapy (BNCT). In this paper, we describe the effectiveness of this treatment, and discuss the ways in which we modified the treatment. A 61-year-old man had a first operation for a right temporal glioblastoma, followed by full-dose chemo-radiotherapy. One year after the operation a partial removal was performed for the recurrent tumor at the same site. Fifty days after the second surgery, the patient received BNCT. We used an epithermal neutron beam as the neutron source, and used both sodium borocapate and boronophenylalanine as boron compounds with the craniotomy. Forty-eight hours after the BNCT, the follow-up MRI was applied to estimate the early effect of this treatment, which showed a 70% reduction in the contrast enhanced lesion, compared with the pretreatment MRI. In addition, the lesion/normal brain ratio of thallium-SPECT had improved markedly. No serial sequelae appeared after this treatment, and the patient remains healthy 6 months after the treatment.
A 29-year-old young lady had a right temporal brain tumor, which was partially resected and followed by stereotactic radiosurgery for the residual mass. Seven months after the radiosurgery, a second operation was performed, which revealed the glioblastoma as diagnosis. We applied BNCT uneventfully for this patient with epithermal beam and two kinds of boron compounds as described above. For the treatment of the patient irradiation was applied without craniotomy with marked reduction of tumor volume immediately after the treatment.
Unable to display preview. Download preview PDF.
- 1.Coderre JA, Morris GM: Review: the radiation biology of boron neutron capture therapy. Radiation Res 151: 1–18, 1999Google Scholar
- 2.Farr LE, Sweet WH, Robertson JS, Foster CG, Locksley JS, Sutherland DL, Mendelsohn ML, Stickley EE: Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol 71: 279–291, 1954Google Scholar
- 3.Asbury AK, Ojeman RG, Nelson SL, Sweet WH: Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 31: 278–303, 1972Google Scholar
- 4.Diaz AZ, Coderre JA, Chanana AD, Ruimei M: Boron neutron capture therapy for malignant gliomas. Ann Med 32: 81–85, 2000Google Scholar
- 5.Kobayashi T, Sakurai Y, Kanda K, Fujita Y, Ono K: The Remodeling and basic characteristics of the Heavy Water Neutron Irradiation Facility of the Kyoto University Research Reactor mainly for neutron capture therapy. Nucl Technol 131: 354–378, 2000Google Scholar
- 6.Ono K, Masunaga SI, Kinashi Y, Takagaki M, Akaboshi M, Kobayashi T, Akuba K: Radiobiological evidence suggesting heterogenous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron therapy. Int J Radiation Biol Phys 34: 1081–1086, 1996Google Scholar
- 7.Ono K, Masunaga SI, Suzuki M, Kinashi Y, Takagaki M, Akaboshi M: The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice. Int J Radiation Biol Phys 43: 431–436, 1999Google Scholar
- 8.Barth RF, Rotaru JH, Stabus AE: Sodium borocaptate and boronophenylalanine alone or in combination as capture 165 agents for BNCT of the rat F98 glioma. In: Mishima Y (ed) Cancer Neutron Capture Therapy. Plenum Press, New York, 1996, pp 769–775Google Scholar
- 9.Wessol D, Cohen M, Harkin G, Rossmeier M, Wemple C, Wheeler F: SERAWorkshop Lab Manual, INEEL/EXT-99-00766, 1999Google Scholar
- 10.Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: Part I. Clin Cancer Res 4: 1825–1832, 1998Google Scholar
- 11.Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: Part II. Clin Cancer Res 4: 1833–1841, 1998Google Scholar
- 12.Chanda M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolosky L, Chanana AD: Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Rad Oncol Biol Phys 40: 829–834, 1998Google Scholar
- 13.Coderre JA, Chanana AD, Joel DD, Elowitz EH, Micca PL, Nawrocky MM, Chadha M, Gebbers JO, Shady M, Peress NS, Slatkin DN: Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiation Res 149: 163–170, 1998Google Scholar
- 14.Barth RF, Yang W, Rotaru JH, Moeschberger ML, Boesel CP, Soloway AH, Joel DD, Nawrocky MM, Ono K, Goodman JH: Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood—brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiation Biol Phys 47: 209–218, 2000Google Scholar
- 15.Shrieve DC, Alexander E 3rd, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS: Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72–77, 1999Google Scholar